drugset / Trial / NCT00804271

Memantine and Validation of a New Alzheimer's Disease Scale

NCT00804271

Phase 3 Completed 487 enrolled Merz Pharmaceuticals GmbH
Non-randomizedSingle-groupOpen-label

Summary

To validate a new Alzheimer's Disease scale against other rating tools in subjects with dementia of Alzheimer's type, treated with memantine.

Timeline

Start
2008-12
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg

Indications